Comparative Pharmacology
Head-to-head clinical analysis: ARISTOCORT A versus DEXONE 0 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOCORT A versus DEXONE 0 5.
ARISTOCORT A vs DEXONE 0.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, suppress cytokine production, and decrease inflammation and immune responses.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor (GR) and modulating gene expression through transactivation and transrepression. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, suppresses cytokine production (IL-1, IL-2, IL-6, TNF-alpha), and decreases immune cell migration and activation.
Intralesional injection: 2.5-5 mg per lesion, repeated every 1-2 weeks. Topical: Apply thin film to affected area 2-4 times daily.
0.5 mg orally once daily, with gradual taper to lowest effective dose
None Documented
None Documented
Terminal half-life: 2-3 hours for triamcinolone acetonide. Clinical context: Duration of action longer due to receptor binding and intracellular activity; anti-inflammatory effects persist 24-48 hours after IM administration.
3.0-4.5 hours; prolonged in hepatic impairment (up to 6-8 hours) or concurrent CYP3A4 inhibitors
Renal: 75% as metabolites (primarily conjugated), 15% as unchanged drug. Biliary/fecal: 10%.
Renal: 70-80% (mostly as 6β-hydroxydexamethasone); biliary/fecal: 10-15%
Category C
Category C
Corticosteroid
Corticosteroid